IP Library Patent Application 14720505
Patent Application
App. No. 14/720,505

ANTIBODY FORMULATIONS AND METHODS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/720,505
Abstract

Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.

Claims (26)

1 - 33 . (canceled)

34 . A nucleic acid comprising a nucleotide sequence encoding at least one polypeptide having an amino acid sequence set forth as any one of SEQ ID NOs: 13-16.

35 . The nucleic acid of claim 34 comprising the nucleotide sequence of SEQ ID NO: 19.

36 . The nucleic acid of claim 35 comprising the nucleotide sequence of SEQ ID NO: 20.

37 - 38 . (canceled)

39 . The nucleic acid of claim 38 comprising the nucleotide sequence of SEQ ID NO: 22.

40 . The nucleic acid of claim 39 comprising the nucleotide sequence of SEQ ID NO: 23.

41 . A vector comprising at least one nucleic acid of claim 34 .

42 . The vector of claim 41 , comprising a nucleic acid comprising a nucleotide sequence encoding a polypeptide having an amino acid sequence set forth as SEQ ID NO: 13 and a nucleic acid comprising a nucleotide sequence encoding a polypeptide having an amino acid sequence set forth as SEQ ID NO: 15.

43 . The vector of claim 41 , comprising a nucleic acid comprising a nucleotide sequence set forth as SEQ ID NO: 19 and a nucleic acid comprising a nucleotide sequence set forth as SEQ ID NO: 22.

44 . The vector of claim 41 , comprising a nucleic acid comprising a nucleotide sequence set forth as SEQ ID NO: 20 and a nucleic acid comprising a nucleotide sequence set forth as SEQ ID NO: 23.

45 . A host cell comprising at least one nucleic acid of claim 34 stably incorporated into its genome.

46 . The host cell of claim 45 , wherein the host cell is a CHO cell.

47 . The host cell of claim 45 having stably incorporated into its genome a nucleic acid comprising a nucleotide sequence encoding a polypeptide having an amino acid sequence set forth as SEQ ID NO: 13 and a nucleic acid comprising a nucleotide sequence encoding a polypeptide having an amino acid sequence set forth as SEQ ID NO: 15.

48 . The host cell of claim 45 having stably incorporated into its genome a nucleic acid comprising a nucleotide sequence set forth as SEQ ID NO: 19 and a nucleic acid comprising a nucleotide sequence set forth as SEQ ID NO: 22.

49 . The host cell of claim 45 having stably incorporated into its genome a nucleic acid comprising a nucleotide sequence set forth as SEQ ID NO: 20 and a nucleic acid comprising a nucleotide sequence set forth as SEQ ID NO: 23.

50 . The host cell of claim 47 , wherein the host cell is a CHO cell.

51 . A method of making a pharmaceutical formulation comprising:

(a) culturing mammalian cells having stably incorporated into their genome one or more nucleic acids encoding a light chain and a heavy chain of a humanized 2A4 antibody so that the mammalian cells secrete the antibody into cell culture media;

(b) purifying the antibody from the cell culture media; and

(c) preparing the pharmaceutical formulation.

52 . The method of claim 51 , wherein the nucleic acid encoding the light chain of a humanized 2A4 antibody comprises a nucleotide sequence encoding a polypeptide having an amino acid sequence set forth as SEQ ID NO: 13, and wherein the nucleic acid encoding the heavy chain of a humanized 2A4 antibody comprises a nucleotide sequence encoding a polypeptide having an amino acid sequence set forth as any one of SEQ ID NOs: 14-16.

53 . The method of claim 52 , wherein the nucleic acid encoding the light chain of a humanized 2A4 antibody comprises a nucleotide sequence encoding a polypeptide having an amino acid sequence set forth as SEQ ID NO: 13, and wherein the nucleic acid encoding the heavy chain of a humanized 2A4 antibody comprises a nucleotide sequence encoding a polypeptide having an amino acid sequence set forth as SEQ ID NO: 15.

54 . The method of claim 53 , wherein the nucleic acid encoding the light chain of a humanized 2A4 antibody comprises a nucleotide sequence of SEQ ID NO: 19, and wherein the nucleic acid encoding the heavy chain of a humanized 2A4 antibody comprises a nucleotide sequence of SEQ ID NO: 22.

55 . The method of claim 54 , wherein the nucleic acid encoding the light chain of a humanized 2A4 antibody comprises a nucleotide sequence of SEQ ID NO: 20, and wherein the nucleic acid encoding the heavy chain of a humanized 2A4 antibody comprises a nucleotide sequence of SEQ ID NO: 23.

56 - 86 . (canceled)

Assignments (4)
CHANGE OF NAME Recorded Nov 20, 2015
From: ONCLAVE THERAPEUTICS
To: PROTHENA THERAPEUTICS LIMITED
Reel/Frame 037104/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2015
From: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
To: ONCLAVE THERAPEUTICS LIMITED
Reel/Frame 036390/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2015
From: HENDERSON, ISAAC CRAIG; KLEIN, PAMELA
To: ONCLAVE THERAPEUTICS LIMITED
Reel/Frame 036357/0843 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2015
From: GARIDEL, PATRICK
To: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
Reel/Frame 036357/0990 →